Bayer's SUNHARBO (asundexian) approved by US FDA to reduce stroke risk
FROM THE WIRE · FINANCE.YAHOO.COM
KEY FACTS The full indication for SUNHARBO® (asundexian) is to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] ≤15) or high-risk transient ischemic attack (TIA) in combination with antiplatelet…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishFDA approval of a first-in-class drug could be relevant for Bayer.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01SUNHARBO 50 mg is approved for adults with recent non-cardioembolic ischemic stroke.
- 02The drug is taken once daily in combination with antiplatelet therapy.
- 03About one in five stroke patients will have another stroke within five years.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets